View in EDS HTML Full Text PDF Full Text

Progression-free survival 3 of 22 months achieved through third-line therapy with adebrelimab in patient with recurrent chordoma: a case report.

Saved in:
Bibliographic Details
Title: Progression-free survival 3 of 22 months achieved through third-line therapy with adebrelimab in patient with recurrent chordoma: a case report.
Authors: Sun L; Department of Pathology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.; School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China., Lang J; Department of Pathology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.; School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China., Zhang W; Department of Pathology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.; School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China., Xiong Z; School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China.; Department of Radiation Oncology, Shaoxing Second Hospital, Shaoxing, Zhejiang, China.
Source: Frontiers in oncology [Front Oncol] 2026 Jun 29; Vol. 16, pp. 1850680. Date of Electronic Publication: 2026 Jun 29 (Print Publication: 2026).
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42444793
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Progression-free survival 3 of 22 months achieved through third-line therapy with adebrelimab in patient with recurrent chordoma: a case report.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sun+L%22">Sun L</searchLink>; Department of Pathology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.; School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China.<br /><searchLink fieldCode="AU" term="%22Lang+J%22">Lang J</searchLink>; Department of Pathology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.; School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China.<br /><searchLink fieldCode="AU" term="%22Zhang+W%22">Zhang W</searchLink>; Department of Pathology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.; School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China.<br /><searchLink fieldCode="AU" term="%22Xiong+Z%22">Xiong Z</searchLink>; School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China.; Department of Radiation Oncology, Shaoxing Second Hospital, Shaoxing, Zhejiang, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2026 Jun 29; Vol. 16, pp. 1850680. <i>Date of Electronic Publication: </i>2026 Jun 29 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Case Reports; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42444793
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2026.1850680
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1850680
    Titles:
      – TitleFull: Progression-free survival 3 of 22 months achieved through third-line therapy with adebrelimab in patient with recurrent chordoma: a case report.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sun L
      – PersonEntity:
          Name:
            NameFull: Lang J
      – PersonEntity:
          Name:
            NameFull: Zhang W
      – PersonEntity:
          Name:
            NameFull: Xiong Z
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 29
              M: 06
              Text: 2026 Jun 29
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1